The ALK1‑Smad1/5‑ID1 pathway participates in tumour angiogenesis induced by low‑dose photodynamic therapy

Guo,Xiya; Niu,Yajuan; Han,Wang; Han,Xiaoyu; Chen,Qing; Tian,Si; Zhu,Ying; Bai,Dingqun; Li,Kaiting

doi:10.3892/ijo.2023.5503

The ALK1‑Smad1/5‑ID1 pathway participates in tumour angiogenesis induced by low‑dose photodynamic therapy

Authors:
- Xiya Guo
- Yajuan Niu
- Wang Han
- Xiaoyu Han
- Qing Chen
- Si Tian
- Ying Zhu
- Dingqun Bai
- Kaiting Li
View Affiliations

Affiliations: Department of Rehabilitation Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: March 15, 2023 https://doi.org/10.3892/ijo.2023.5503
Article Number: 55
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Photodynamic therapy (PDT) is an effective and low‑invasive tumour therapy. However, it can induce tumour angiogenesis, which is a main factor leading to tumour recurrence and metastasis. Activin receptor‑like kinase‑1 (ALK1) is a key factor regulating angiogenesis. However, it remains unclear whether ALK1 plays an unusual role in low‑dose PDT‑induced tumour angiogenesis. In the present study, human umbilical vein endothelial cells (HUVECs) co‑cultured with breast cancer MDA‑MB‑231 cells (termed HU‑231 cells) were used to construct an experimental model of tumour angiogenesis induced by low‑dose PDT. The viability, and the proliferative, invasive, migratory, as well as the tube‑forming ability of the HU‑231 cells were evaluated following low‑dose PDT. In particular, ALK1 inhibitor and and an adenovirus against ALK1 were used to further verify the role of ALK1 in low‑dose PDT‑induced tumour angiogenesis. Moreover, the expression of ALK1, inhibitor of DNA binding 1 (ID1), Smad 1, p‑Smad1/5, AKT and PI3K were detected in order to verify the underlying mechanisms. The findings indicated that low‑dose PDT enhanced the proliferative ability of the HU‑231 cells and reinforced their migratory, invasive and tube formation capacity. However, these effects were reversed with the addition of an ALK1 inhibitor or by the knockdown of ALK1 using adenovirus. These results indicated that ALK1 was involved and played a critical role in tumour angiogenesis induced by low‑dose PDT. Furthermore, ALK1 was found to participate in PDT‑induced tumour angiogenesis by activating the Smad1/5‑ID1 pathway, as opposed to the PI3K/AKT pathway. On the whole, the present study, for the first time, to the best of our knowledge, demonstrates that ALK1 is involved in PDT‑induced tumour angiogenesis. The inhibition of ALK1 can suppress PDT‑induced tumour angiogenesis, which can enhance the effects of PDT and may thus provide a novel treatment strategy for PDT.

View Figures

View References

1	Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, Hahn SM, Hamblin MR, Juzeniene A, Kessel D, et al: Photodynamic therapy of cancer: An update. CA Cancer J Clin. 61:250–281. 2011. View Article : Google Scholar : PubMed/NCBI
2	Li L, Song D, Qi L, Jiang M, Wu Y, Gan J, Cao K, Li Y, Bai Y and Zheng T: Photodynamic therapy induces human esophageal carcinoma cell pyroptosis by targeting the PKM2/caspase-8/caspase-3/GSDME axis. Cancer Lett. 520:143–159. 2021. View Article : Google Scholar : PubMed/NCBI
3	Simone CB II and Cengel KA: Photodynamic therapy for lung cancer and malignant pleural mesothelioma. Semin Oncol. 41:820–830. 2014. View Article : Google Scholar : PubMed/NCBI
4	Gamelas SR, Moura NM, Habraken Y, Piette J, Neves M and Faustino MA: Tetracationic porphyrin derivatives against human breast cancer. J Photochem Photobiol B. 222:1122582021. View Article : Google Scholar : PubMed/NCBI
5	Leon D, Buchegger K, Silva R, Riquelme I, Viscarra T, Mora-Lagos B, Zanella L, Schafer F, Kurachi C, Roa JC, et al: Epigallocatechin gallate enhances MAL-PDT cytotoxic effect on PDT-resistant skin cancer squamous cells. Int J Mol Sci. 21:33272020. View Article : Google Scholar : PubMed/NCBI
6	Broekgaarden M, Weijer R, van Gulik TM, Hamblin MR and Heger M: Tumor cell survival pathways activated by photodynamic therapy: A molecular basis for pharmacological inhibition strategies. Cancer Metastasis Rev. 34:643–690. 2015. View Article : Google Scholar : PubMed/NCBI
7	Wan Y, Fu LH, Li C, Lin J and Huang P: Conquering the hypoxia limitation for photodynamic therapy. Adv Mater. 33:e21039782021. View Article : Google Scholar : PubMed/NCBI
8	Yue D, Cai X, Fan M, Zhu J, Tian J, Wu L, Jiang Q and Gu Z: An alternating irradiation strategy-driven combination therapy of PDT and RNAi for highly efficient inhibition of tumor growth and metastasis. Adv Healthc Mater. 10:e20018502021. View Article : Google Scholar
9	De Sanctis F, Ugel S, Facciponte J and Facciabene A: The dark side of tumor-associated endothelial cells. Semin Immunol. 35:35–47. 2018. View Article : Google Scholar : PubMed/NCBI
10	Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS and Gomer CJ: Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 60:4066–4069. 2000.PubMed/NCBI
11	Peng CL, Lin HC, Chiang WL, Shih YH, Chiang PF, Luo TY, Cheng CC and Shieh MJ: Anti-angiogenic treatment (Bevacizumab) improves the responsiveness of photodynamic therapy in colorectal cancer. Photodiagnosis Photodyn Ther. 23:111–118. 2018. View Article : Google Scholar : PubMed/NCBI
12	Olivo M, Bhuvaneswari R, Lucky SS, Dendukuri N and Soo-Ping Thong P: Targeted therapy of cancer using photodynamic therapy in combination with multi-faceted anti-tumor modalities. Pharmaceuticals (Basel). 3:1507–1529. 2010. View Article : Google Scholar : PubMed/NCBI
13	Shimizu K, Asai T and Oku N: Antineovascular therapy, a novel antiangiogenic approach. Expert Opin Ther Targets. 9:63–76. 2005. View Article : Google Scholar : PubMed/NCBI
14	Weiss A, den Bergh Hv, Griffioen AW and Nowak-Sliwinska P: Angiogenesis inhibition for the improvement of photodynamic therapy: The revival of a promising idea. Biochim Biophys Acta. 1826:53–70. 2012.PubMed/NCBI
15	Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, Wickman G, Chen JH, Wang J, Jiang X, et al: Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res. 71:1362–1373. 2011. View Article : Google Scholar : PubMed/NCBI
16	de Vinuesa AG, Bocci M, Pietras K and Ten Dijke P: Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function. Biochem Soc Trans. 44:1142–1149. 2016. View Article : Google Scholar : PubMed/NCBI
17	Roman BL and Hinck AP: ALK1 signaling in development and disease: New paradigms. Cell Mol Life Sci. 74:4539–4560. 2017. View Article : Google Scholar : PubMed/NCBI
18	Bhatt RS and Atkins MB: Molecular pathways: Can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors? Clin Cancer Res. 20:2838–2845. 2014. View Article : Google Scholar : PubMed/NCBI
19	Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L, Goumans MJ, Seehra J, Heldin CH, ten Dijke P and Pietras K: Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J Exp Med. 207:85–100. 2010. View Article : Google Scholar : PubMed/NCBI
20	Hawinkels LJ, de Vinuesa AG, Paauwe M, Kruithof-de Julio M, Wiercinska E, Pardali E, Mezzanotte L, Keereweer S, Braumuller TM, Heijkants RC, et al: Activin receptor-like kinase 1 ligand trap reduces microvascular density and improves chemotherapy efficiency to various solid tumors. Clin Cancer Res. 22:96–106. 2016. View Article : Google Scholar
21	Cunha SI, Bocci M, Lövrot J, Eleftheriou N, Roswall P, Cordero E, Lindström L, Bartoschek M, Haller BK, Pearsall RS, et al: Endothelial ALK1 is a therapeutic target to block metastatic dissemination of breast cancer. Cancer Res. 75:2445–2456. 2015. View Article : Google Scholar : PubMed/NCBI
22	Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, et al: A Phase I study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) monoclonal antibody PF-03446962 in patients with advanced solid tumors. Clin Cancer Res. 22:2146–2154. 2016. View Article : Google Scholar
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
24	Alzeibak R, Mishchenko TA, Shilyagina NY, Balalaeva IV, Vedunova MV and Krysko DV: Targeting immunogenic cancer cell death by photodynamic therapy: Past, present and future. J Immunother Cancer. 9:e0019262021. View Article : Google Scholar : PubMed/NCBI
25	Weijer R, Clavier S, Zaal EA, Pijls MM, van Kooten RT, Vermaas K, Leen R, Jongejan A, Moerland PD, van Kampen AH, et al: Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy. Cell Mol Life Sci. 74:1133–1151. 2017. View Article : Google Scholar :
26	Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J and Peng Q: Photodynamic therapy. J Natl Cancer Inst. 90:889–905. 1998. View Article : Google Scholar : PubMed/NCBI
27	Blazquez-Castro A, Carrasco E, Calvo MI, Jaén P, Stockert JC, Juarranz A, Sánz-Rodríguez F and Espada J: Protoporphyrin IX-dependent photodynamic production of endogenous ROS stimulates cell proliferation. Eur J Cell Biol. 91:216–223. 2012. View Article : Google Scholar : PubMed/NCBI
28	Espada J, Galaz S, Sanz-Rodríguez F, Blázquez-Castro A, Stockert JC, Bagazgoitia L, Jaén P, González S, Cano A and Juarranz A: Oncogenic H-Ras and PI3K signaling can inhibit E-cadherin-dependent apoptosis and promote cell survival after photodynamic therapy in mouse keratinocytes. J Cell Physiol. 219:84–93. 2009. View Article : Google Scholar
29	Udartseva OO, Zhidkova OV, Ezdakova MI, Ogneva IV, Andreeva ER, Buravkova LB and Gollnick SO: Low-dose photodynamic therapy promotes angiogenic potential and increases immunogenicity of human mesenchymal stromal cells. J Photochem Photobiol B. 199:1115962019. View Article : Google Scholar : PubMed/NCBI
30	Zhang X, Jiang F, Zhang ZG, Kalkanis SN, Hong X, deCarvalho AC, Chen J, Yang H, Robin AM and Chopp M: Low-dose photodynamic therapy increases endothelial cell proliferation and VEGF expression in nude mice brain. Lasers Med Sci. 20:74–79. 2005. View Article : Google Scholar : PubMed/NCBI
31	Muñoz-Félix JM, González-Núñez M and López-Novoa JM: ALK1-Smad1/5 signaling pathway in fibrosis development: Friend or foe? Cytokine Growth Factor Rev. 24:523–537. 2013. View Article : Google Scholar : PubMed/NCBI
32	Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, et al: Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 13:189–195. 1996. View Article : Google Scholar : PubMed/NCBI
33	Urness LD, Sorensen LK and Li DY: Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat Genet. 26:328–331. 2000. View Article : Google Scholar : PubMed/NCBI
34	Scharpfenecker M, van Dinther M, Liu Z, van Bezooijen RL, Zhao Q, Pukac L, Löwik CW and ten Dijke P: BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci. 120:964–972. 2007. View Article : Google Scholar : PubMed/NCBI
35	Fu Y, Wang H, Dai H, Zhu Q, Cui CP, Sun X, Li Y, Deng Z, Zhou X, Ge Y, et al: OTULIN allies with LUBAC to govern angiogenesis by editing ALK1 linear polyubiquitin. Mol Cell. 81:3187–3204.e7. 2021. View Article : Google Scholar : PubMed/NCBI
36	Somekawa S, Imagawa K, Hayashi H, Sakabe M, Ioka T, Sato GE, Inada K, Iwamoto T, Mori T, Uemura S, et al: Tmem100, an ALK1 receptor signaling-dependent gene essential for arterial endothelium differentiation and vascular morphogenesis. Proc Natl Acad Sci USA. 109:12064–12069. 2012. View Article : Google Scholar : PubMed/NCBI
37	Li W, Salmon RM, Jiang H and Morrell NW: Regulation of the ALK1 ligands, BMP9 and BMP10. Biochem Soc Trans. 44:1135–1141. 2016. View Article : Google Scholar : PubMed/NCBI
38	Hou X, Peng Y, Liu J, Zhong Q, Yu Z and Zhang L: Bone morphogenetic protein-9 promotes the proliferation of non-small cell lung cancer cells by activating PI3K/Akt and Smad1/5 pathways. RSC Adv. 10:7214–7220. 2020. View Article : Google Scholar : PubMed/NCBI
39	Ola R, Dubrac A, Han J, Zhang F, Fang JS, Larrivée B, Lee M, Urarte AA, Kraehling JR, Genet G, et al: PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nat Commun. 7:136502016. View Article : Google Scholar : PubMed/NCBI
40	Chen H, Pan R, Li H, Zhang W, Ren C, Lu Q, Chen H, Zhang X and Nie Y: CHRDL2 promotes osteosarcoma cell proliferation and metastasis through the BMP-9/PI3K/AKT pathway. Cell Biol Int. 45:623–632. 2021. View Article : Google Scholar :
41	Gong T, Cui L, Wang H, Wang H and Han N: Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. J Transl Med. 16:1642018. View Article : Google Scholar